Celltrion presents efficacy and safety data for potential COVID-19 treatment candidate CT-P59 in patients with mild symptoms
Celltrion Group announced results from the ongoing Phase I clinical trial of CT-P59, an anti-COVID-19 monoclonal antibody treatment candidate. The data presented at the 2020 fall Conference of the Korean Society of Infectious Diseases on 5th November 2020, demonstrated promising safety, tolerability, antiviral effect, and efficacy profile of CT-P59 in patients with mild symptoms of COVID-19.
The global Phase I clinical trial is a randomised, double-blind, placebo-controlled and parallel-group trial designed to evaluate the safety, tolerability and antiviral effect of CT-P59. The trial enrolled 18 patients with mild symptoms of SARS-COV-2 infection who were randomised into three cohorts in which 15 patients received CT-P59 at 20mg/kg, 40mg/kg or 80mg/kg respectively, or matching placebo (3 patients).
The results indicate that the patient population treated with CT-P59 experienced about 44% reduced mean clinical recovery time in comparison to the average placebo recovery time. None of the patients treated with CT-P59 required hospitalisation or antiviral therapy as a result of COVID-19. No significant treatment-emergent serious adverse events or clinically significant treatment-emergent adverse events were identified at the interim stage.
“This is positive and encouraging efficacy and safety data showing accelerated recovery time in patients with mild symptoms of COVID-19,” said Professor Jin Yong Kim, Division of Infectious Diseases, Department of Internal Medicine, Incheon Medical Centre. “I look forward to the possibility of further promising data from ongoing phase II/III studies building on the positive results seen in this study.”
Celltrion has previously submitted the Investigational New Drug (IND) application for the clinical trial globally, and plans to conduct further global Phase II and III trials including Korea. In addition, Celltrion has also initiated a post-exposure prophylaxis clinical trial of CT-P59 to evaluate the candidate as a protective treatment, by investigating the efficacy of the treatment in those who have been in contact with confirmed SARS-CoV-2 infected patients.
- ENDS -
Notes to Editors:
About Celltrion Healthcare
Celltrion Healthcare is committed to delivering innovative and affordable medications to promote patients’ access to advanced therapies. Its products are manufactured at state-of-the-art mammalian cell culture facilities, designed and built to comply with the US FDA cGMP and the EU GMP guidelines. Celltrion Healthcare endeavours to offer high-quality cost-effective solutions through an extensive global network that spans more than 110 different countries. For more information please visit: https://www.celltrionhealthcare.com/en-us
Coronaviruses (CoV) are a family of viruses that lead to illnesses from the common cold to severe diseases. Novel coronavirus SARS-CoV-2 is responsible for the disease COVID-19, this new strain, discovered in 2019, is behind the ongoing pandemic outbreak.
The most common signs of COVID-19 include fever, dry cough and tiredness; however, people may also experience other symptoms including shortness of breath and breathing difficulties. Most people infected with the virus will exhibit mild to moderate symptoms however older people, and those with existing underlying conditions such as cardiovascular disease and diabetes are more likely to develop a more severe form of COVID-19.
Please find up to date information about the outbreak via the World Health Organization at https://www.who.int/health-topics/coronavirus#tab=tab_1
CT-P59 was identified as a potential treatment for COVID-19 through screening of antibody candidates and selecting those that showed the highest potency in neutralising the SARS-CoV-2 virus including the mutated G-variant strain (D614G variant). In pre-clinical data the treatment candidate demonstrated a 100-fold reduction in viral load of SARS-CoV-2, as well as a reduction in lung inflammation.3
1 Coronavirus. World Health Organization. Available at: https://www.who.int/health-topics/coronavirus#tab=tab_1 Last accessed: November 2020
2 Coronaviruses. National Institute of Allergy and Infectious Diseases. Available at: https://www.niaid.nih.gov/diseases-conditions/coronaviruses Last accessed: November 2020
3 Celltrion. Data on file
+44 (0) 20 3817 6766
+44 (0) 7506 339043
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Rand Technology Appoints Key Executives Across Global Regions4.12.2020 00:30:00 CET | Press release
Rand Technology (Rand) has appointed Kim Fix, Chief Operating Officer (COO), Americas & Europe; Frederick Fu, President and Managing Director, Asia-Pacific (APAC); Nami Mokri, Vice President, Sales & Sourcing, APAC; Kevin Sheehan, Chief Information Officer (CIO); and Jennifer Strawn, Director, Sourcing & Procurement, Americas & Europe. Kim Fix, Global Vice President, QA & Operations, has been appointed to COO, Americas & Europe. Kim will lead Rand’s sales and sourcing teams’ operations across the Americas and Europe and oversee global compliance, quality assurance, and operations. Kim has been integral to Rand’s preferred status with its business partners and multi-site ISO, OHSAS, ANSI ESD, and R2 certifications. Frederick Fu joined Rand as President and Managing Director, APAC. He previously served as Avnet’s President of APAC. He has been fundamental to Rand’s efficacy, growth, strategy, and success in the APAC region. Nami Mokri was appointed Vice President, Sales & Sourcing, APAC.
Kalray Joins MLCommons as Founding Member3.12.2020 18:30:00 CET | Press release
Kalray (Euronext Growth Paris: FR0010722819 – ALKAL) (Paris:ALKAL), a pioneer in processors for new intelligent systems, today announced it has joined MLCommons as founding member. MLCommons is a not for profit, engineering consortium founded by 30+ global technology and academic leaders in AI and Machine Learning to accelerate machine learning innovation and broaden access to this critical technology for the public good. Initially formed as MLPerf, MLCommons boasts a founding board that includes representatives from Alibaba, Facebook AI, Google, Intel, NVIDIA and Professor Vijay Janapa Reddi of Harvard University with the objective to deliver industry-wide benchmarks, best practices and datasets to speed computer vision, natural language processing, and speech recognition development for all. “MLCommons has a clear mission - accelerate Machine Learning innovation to ‘raise all boats’ and increase its positive impact on society” said Peter Mattson, President of MLCommons. “We are excit
Hyperloop Transportation Technologies Accelerates with 100 Engineers from World Leading Firm Altran3.12.2020 17:40:00 CET | Press release
Hyperloop Transportation Technologies (HyperloopTT) announced today an agreement with world-leading engineering and R&D services provider Altran, part of the Capgemini Group. The agreement includes one hundred Altran engineers to accelerate the development of commercialized passenger hyperloop systems at the HyperloopTT facility in Toulouse, France, the Aerospace Valley of Europe. HyperloopTT’s European R&D Center is the home of the world’s only full-scale hyperloop system, which has been undergoing testing and optimization since 2019. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201203005174/en/ HyperloopTT's full-scale test system in Toulouse, France (Photo: Business Wire) The agreement advances HyperloopTT’s capabilities in a lean way, negotiated within HyperloopTT’s hybrid collaborative framework. The announcement comes after recent commitments from both the European Union and the United States, emphasizing the develop
Dan Bilzerian Joins Team GGPoker & Celebrates With $100,000 Birthday Freeroll3.12.2020 17:00:00 CET | Press release
GGPoker today announces that Dan Bilzerian has joined Team GGPoker as a brand ambassador. One of the world’s most recognizable poker players and social media influencers, with over 32 million followers on Instagram, “Blitz” will represent GGPoker live and online. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201203005724/en/ Dan Bilzerian, GGPoker's newest brand ambassador. (Photo: Business Wire) To celebrate the news, the online poker room will host a special 40th birthday party for the ‘King of Instagram’ on December 7 in the form of a $100,000 Birthday Freeroll poker tournament. This free-to-enter poker game is open to all new GGPoker players that sign up using code BLITZ40 and deposit $10 or more. What: Dan’s $100,000 Birthday Freeroll When: Monday, December 7 at 17:00 UTC How To Enter: Sign up using code BLITZ40, deposit at least $10 and use your ticket to register for the freeroll tournament Tournament Prize Pool: $10
Odense Investor Summit Introduces Investors to 15 Promising Robot Companies in Europe’s Robot Capital3.12.2020 16:47:00 CET | Press release
In just five years, robotic start-ups based in Odense, Denmark – the robot capital of Europe – have attracted more than 976 million USD. This year, the local Danish entrepreneurs will be joined by companies from the RobotUnion Super Stars; finalists from the pan-European robot acceleration program. The event is being sponsored by Vækstfonden, the Danish State’s investment fund, with the objective of making matches between leading Danish entrepreneurs seeking capital backing, and top international investors on the hunt for the next “golden goose” in the world of robotics. On December 9th, a carefully selected field of robot enterprises seeking capital will be presenting their ground-breaking automation solutions for a broad spectrum of industries at this year’s Odense Investor Summit. The 2020 summit is being held as a virtual event to involve participants from all parts of Europe and provide access to a new audience while still observing the prevailing COVID-19 restrictions. In additio
IEEE Launches 802.3™ Beyond 400Gb/s Ethernet Study Group to Define Next High Speed Threshold for Ethernet Data Rate3.12.2020 16:30:00 CET | Press release
IEEE, the world's largest technical professional organization dedicated to advancing technology for humanity, and IEEE Standards Association (IEEE SA) today announced the formation of a study group within the IEEE 802.3™ Ethernet Working Group. With bandwidth demand growing across all areas of Ethernet connectivity globally, the IEEE 802.3 Beyond 400Gb/s Ethernet Study Group will explore initiating a new IEEE project that would standardize capabilities exceeding today’s maximum data rate of 400 Gigabit per second (Gb/s) for https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fstandards.ieee.org%2Fstandard%2F802_3-2018.html%3Futm_source%3Dbusinesswire%26utm_medium%3Dpr%26utm_campaign%3Dworking-group-2020%26utm_content%3D802&esheet=52341781&newsitemid=20201203005124&lan=en-US&anchor=IEEE+802.3%2C+IEEE+Standard+for+Ethernet&index=2&md5=214f246922adc89c9023ea7f9b810359 IEEE 802.3, IEEE Standard for Ethernet. The publicly available IEEE 802.3™ Ethernet Bandwidth Assessment (BWA
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.Visit our pressroom